Articles by Tim Freeman - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Tim Freeman

Tim Freeman

Tim Freeman is Managing Director for Freeman Technology.

Tableting—a Focus for Continuous Improvement
August 1, 2014

Efforts to tackle challenges in tablet manufacture are shaped by quality by design (QbD) and continuous manufacturing.

Powder Testing Techniques for Tablet Manufacture
March 1, 2012

This article considers the different conditions to which the powder is subjected in the tableting process, and discusses which powder properties should be measured to accurately reflect likely powder behavior in the process.

Under Continuous Consideration
November 1, 2011

Continuous manufacturing is increasingly noted as an important long-term objective for the pharmaceutical industry. PTE talks with Tim Freeman, Director of Operations at Freeman Technology, about some of the central issues involved in this transition, as well as the supporting role of relevant analytical technology.

Correlating Die-Filling Performance with Powder Properties
April 1, 2011

The author explains how to gain an understanding of the relationships between powder characteristics and process performance to match filling-machine geometry to the demands of specific formulations.

Establishing Endpoints
March 7, 2011

The unit selected for wet granulation, whether it be a high shear mixer or a fluidised bed, has a marked impact on granule properties.

Applying Real Time Release Testing to Powder Processing
February 2, 2011

How to adapt a real time release approach to powder processing during drug-product manufacturing.

The importance of powder characterization
June 1, 2010

How effective powder characterization can lead to better powder understanding and control.

Understanding powder behaviour
May 1, 2010

The needs of the pharmaceutical industry for powder testing technologies are changing, primarily for two reasons. The first is that global economics, and the economics and competitiveness of the pharmaceutical industry itself, are driving manufacturers towards achieving greater efficiency.

Understanding powder behaviour
May 1, 2010

The needs of the pharmaceutical industry for powder testing technologies are changing, primarily for two reasons.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here